Certain inactivating mutations in tumor suppressors are heterozygous germline variants, but show loss of heterozygosity in the tumor.42 Five of TP53 SLG variants exhibit evidence of loss of heterozygosity, with germline VAFs below 45% and tumor VAFs above 70%. Here, TP53 is linked to neoplasm.